产品
编 号：F763013
分子式：C32H40N4O6S2
分子量：640.81
分子式：C32H40N4O6S2
分子量：640.81
产品类型
规格
价格
是否有货
结构图
CAS No: 3020773-81-0
产品详情
生物活性：
PROTAC CDK9/CycT1 Degrader-1 (compounds 10) is a potent inhibitor of CDK9. PROTAC CDK9/CycT1 Degrader-1 can be used as a PROTAC target protein ligand for PROTAC synthesis. PROTAC CDK9/CycT1 Degrader-1 shows strong anti-proliferative activity in solid tumors.
体内研究：
CDK9-IN-28 (5 mg/kg，腹腔注射，每天一次持续15天)在 MV4-11 肿瘤裸鼠模型中抑制了肿瘤生长。CDK9-IN-28 (1 mg/kg，静脉注射，5 mg/kg，腹腔注射)在 ICR (CD-1) 小鼠模型中显示出可接受的半衰期(T1/2:4.66h)和中等的生物利用度(F=43.1%)。Animal Model:MV4-11 tumor nude mice
Dosage:5 mg/kg
Administration:Intraperitoneal injection, once a day for 15 days.
Result:Effective delayed of tumor growth but weight did not lose.
体外研究：
CDK9-IN-28 在 U-2932 细胞中表现出明显的 CDK9 降解，在肿瘤中具有明显的抗增殖活性。
PROTAC CDK9/CycT1 Degrader-1 (compounds 10) is a potent inhibitor of CDK9. PROTAC CDK9/CycT1 Degrader-1 can be used as a PROTAC target protein ligand for PROTAC synthesis. PROTAC CDK9/CycT1 Degrader-1 shows strong anti-proliferative activity in solid tumors.
体内研究：
CDK9-IN-28 (5 mg/kg，腹腔注射，每天一次持续15天)在 MV4-11 肿瘤裸鼠模型中抑制了肿瘤生长。CDK9-IN-28 (1 mg/kg，静脉注射，5 mg/kg，腹腔注射)在 ICR (CD-1) 小鼠模型中显示出可接受的半衰期(T1/2:4.66h)和中等的生物利用度(F=43.1%)。Animal Model:MV4-11 tumor nude mice
Dosage:5 mg/kg
Administration:Intraperitoneal injection, once a day for 15 days.
Result:Effective delayed of tumor growth but weight did not lose.
体外研究：
CDK9-IN-28 在 U-2932 细胞中表现出明显的 CDK9 降解，在肿瘤中具有明显的抗增殖活性。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备